InSea2 Impacts Glycemic Response

In a recent randomized, crossover, double-blind, placebo-controlled human clinical trial led by the Institute of Nutraceuticals and Functional Foods of Laval University (Quebec, Canada), InSea2, from innoVactiv (at a single dose of 500 mg), induced a statistically significant 44% decrease in the normal glycemic response that follows ingestion of a standardized meal (white bread) in 23 healthy volunteers. InSea2 also induced a 22% reduction in initial insulin production and an overall 6% reduction in the area under the curve of the insulin response. Additionally, InSea2 improved insulin sensitivity by nearly 7% (Cederholm index) after a single use of the product. For further information: www.innovactiv.com